Novartis has released preliminary results from the RELAX-AHF trial, a phase 3 study of a novel drug, RLX030 (serelaxin), for patients hospitalized with acute heart failure. The full trial results are scheduled to be presented as a late-breaking clinical trial at the American Heart Association meeting in Los Angeles in November.

According to Novartis, the six-month trial met one of its two primary endpoints in reducing dyspnea and showed RLX030 was well tolerated. The company also reported a reduction in all-cause mortality at six months. However, there was no information on all-cause mortality at 60 days – a predefined secondary endpoint.

The trial is based on 1,161 patients hospitalized with acute heart failure who were randomized to placebo or an IV infusion of RLX030 for up to 48 hours.

< Back to Listings